Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The stock is up by about 191% over the past five years compared to a 94% gain from the benchmark S&P 500 index.

Wall Street likes the company's promising pipeline ... this weight-loss drug stock could more than 3x over the next 12 months -- and it's not Eli Lilly or Novo Nordisk. The great expectations for Viking Therapeutics aren't limited to only a few outlier ...